Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Gyre Therapeutics's Enterprise Value is €576.1 Mil.
Gyre Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was €-6.4 Mil. Therefore, Gyre Therapeutics's EV-to-FCF for today is -90.71.
The historical rank and industry rank for Gyre Therapeutics's EV-to-FCF or its related term are showing as below:
STU:L9S'
s EV-to-FCF Range Over the Past 10 Years
Min: -929.03 Med: 35.68 Max: 664.94
Current: -93.05
During the past 5 years, the highest EV-to-FCF of Gyre Therapeutics was 664.94. The lowest was -929.03. And the median was 35.68.
STU:L9S's EV-to-FCF is ranked worse than 100% of 332
companies
in the Biotechnology industry
Industry Median: 17.465
vs STU:L9S: -93.05
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Gyre Therapeutics's PE Ratio (TTM) for today is calculated as:
Gyre Therapeutics's share price for today is €5.75.
Gyre Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.181.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Gyre Therapeutics EV-to-FCF Related Terms
Gyre Therapeutics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Gyre Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Gyre Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gyre Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Gyre Therapeutics's EV-to-FCF falls into.
Gyre Therapeutics's current Enterprise Value is €576.1 Mil.
Gyre Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-6.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gyre Therapeutics (STU:L9S) has a EV-to-FCF of -90.71 as of Aug. 12, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Gyre Therapeutics and its competitors. According to the industry distribution chart, Gyre Therapeutics ranks #999999 out of 332 companies in the Biotechnology industry.
Is Gyre Therapeutics' EV-to-FCF too high?
Gyre Therapeutics' current EV-to-FCF is -90.71. Based on the distribution chart, Gyre Therapeutics ranks #999999 out of 332 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Gyre Therapeutics has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Gyre Therapeutics' EV-to-FCF compare to OCS and RIGL?
According to the Biotechnology industry distribution chart, Gyre Therapeutics ranks #999999 out of 332 companies for EV-to-FCF. This places Gyre Therapeutics in the lower half of its industry. The industry median EV-to-FCF is 17.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 17.47, based on 332 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Gyre Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 17.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gyre Therapeutics's current EV-to-FCF is -90.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gyre Therapeutics stock overvalued right now?
Gyre Therapeutics (STU:L9S) has a current EV-to-FCF of -90.71. The stock's GF Value™ is €7.95, compared to a current price of €5.75 — trading 27.7% below its estimated fair value. The current EV-to-FCF is -90.71. Gyre Therapeutics' overall GF Score™ is 39/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Gyre Therapeutics (STU:L9S), the current EV-to-FCF is -90.71 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gyre Therapeutics (STU:L9S) Overvalued in 2026?
Based on GuruFocus' analysis, Gyre Therapeutics stock appears to be undervalued.
The current stock price of €5.75 is trading 27.7% below its estimated GF Value™ of €7.95.
Key valuation signals for STU:L9S:
EV-to-FCF: -90.71
GF Value™: €7.95 vs. price of €5.75 (27.7% below fair value)
No single metric tells the full story. See the STU:L9S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
39GF Score
Get the complete analysis for STU:L9S
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:L9S has been successfully added to your 
